Knee issues/arthritis runner; Swelling in right hand; This spontaneous case was reported by a consumer and describes the occurrence of ARTHRITIS (Knee issues/arthritis runner) and PERIPHERAL SWELLING (Swelling in right hand) in an adult male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Psoriatic arthritis and Rheumatoid arthritis.    The patient's past medical history included Knee injury (Could not run/knees were shot). Concurrent medical conditions included Psoriatic arthritis and Rheumatoid arthritis (Moderate to severe).   On 26-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 26-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) Citrate Free (1 in 2 wk). On an unknown date, ADALIMUMAB (HUMIRA) (Subcutaneous) dosage was changed to Citrate Free (1 in 10 D). On an unknown date, the patient experienced ARTHRITIS (Knee issues/arthritis runner) and PERIPHERAL SWELLING (Swelling in right hand). At the time of the report, ARTHRITIS (Knee issues/arthritis runner) and PERIPHERAL SWELLING (Swelling in right hand) had not resolved.            No relevant concomitant medications were reported. No treatment medication reported. It was unknown if patient was enrolled in a COVID-19 Vaccine Trial.  The reporter's causality for the event(s) of KNEE ISSUES/ARTHRITIS RUNNER with HUMIRA(ADALIMUMAB) was no reasonable possibility. The reporter's causality for the event(s) of SWELLING IN RIGHT HAND was not provided.  This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.  Company Comment: This spontaneous case concerns an adult male patient of unspecified age with relevant past medical history of Knee injury and concurrent medical condition of Psoriatic arthritis and Rheumatoid arthritis that was treated with Adalimumab (Humira), who experienced the unexpected, non-serious AESI of Arthritis and non-serious event of Peripheral swelling. The events occurred on an unknown date in context to second dose of mRNA-1273 vaccine. Latency cannot be assessed since event onset date was not disclosed. The Clinical course and treatment details were not provided, and the event outcome was not resolved. The relevant past medical history of Knee injury and concurrent medical condition of Psoriatic arthritis and Rheumatoid arthritis that was treated with Adalimumab (Humira) the co-suspect remains a confounder to the event arthritis. The benefit-risk relationship of the mRNA-1273 vaccine is not affected by this report. Events seriousness was assessed as per medical judgement and available information.; Sender's Comments: This spontaneous case concerns an adult male patient of unspecified age with relevant past medical history of Knee injury and concurrent medical condition of Psoriatic arthritis and Rheumatoid arthritis that was treated with Adalimumab (Humira), who experienced the unexpected, non-serious AESI of Arthritis and non-serious event of Peripheral swelling. The events occurred on an unknown date in context to second dose of mRNA-1273 vaccine. Latency cannot be assessed since event onset date was not disclosed. The Clinical course and treatment details were not provided, and the event outcome was not resolved. The relevant past medical history of Knee injury and concurrent medical condition of Psoriatic arthritis and Rheumatoid arthritis that was treated with Adalimumab (Humira) the co-suspect remains a confounder to the event arthritis. The benefit-risk relationship of the mRNA-1273 vaccine is not affected by this report. Events seriousness was assessed as per medical judgement and available information.